Rani Therapeutics Holdings (RANI) Long-Term Debt Issuances (2020 - 2022)

Rani Therapeutics Holdings' (RANI) quarterly Long-Term Debt Issuances came in at $14.9 million in Q4 2022, up 1.58% quarter-over-quarter from $14.7 million in Q3 2022.

Rani Therapeutics Holdings (RANI) Long-Term Debt Issuances (2020 - 2022) Analysis & Trends

Rani Therapeutics Holdings' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $14.9 million for Q4 2022.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $14.9 million in Q4 2022; TTM through Dec 2023 was $29.6 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $29.6 million, up 1619.42% from the prior year.
  • Long-Term Debt Issuances climbed to $14.9 million in Q4 2022 per RANI's latest filing, from $14.7 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $14.9 million in Q4 2022 and bottomed at -$1.5 million in Q4 2020.
  • The 3-year median for Long-Term Debt Issuances is $2.8 million (2020), against an average of $6.5 million.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Rani Therapeutics Holdings 160.20 Mn 167.33 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 14.90 Mn
Dec 31, 2022 14.90 Mn
Sep 30, 2022 14.67 Mn
Sep 30, 2022 14.67 Mn
Mar 31, 2021 1.72 Mn
Mar 31, 2021 1.72 Mn
Dec 31, 2020 -1.53 Mn
Dec 31, 2020 -1.53 Mn
Sep 30, 2020 2.78 Mn
Sep 30, 2020 2.78 Mn